These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23184699)

  • 1. Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).
    Hammes SR; Krymskaya VP
    Horm Cancer; 2013 Apr; 4(2):70-7. PubMed ID: 23184699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
    Krymskaya VP
    Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM).
    Krymskaya VP
    Expert Opin Orphan Drugs; 2014 Oct; 2(10):1063-1074. PubMed ID: 26779398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular insights into lymphangioleiomyomatosis.
    Steagall WK; Taveira-DaSilva AM; Moss J
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.
    Sathirareuangchai S; Shimizu D; Vierkoetter KR
    Hawaii J Health Soc Welf; 2020 Jul; 79(7):224-229. PubMed ID: 32666056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment.
    Meraj R; Wikenheiser-Brokamp KA; Young LR; McCormack FX
    Semin Respir Crit Care Med; 2012 Oct; 33(5):486-97. PubMed ID: 23001803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
    Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
    Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pulmonary lymphangioleiomyomatosis with or without tuberous sclerosis].
    Urban T
    Rev Mal Respir; 2007 Jun; 24(6):725-40. PubMed ID: 17632432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
    Goncharova EA; Krymskaya VP
    J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare lung diseases I--Lymphangioleiomyomatosis.
    Juvet SC; Hwang D; Downey GP
    Can Respir J; 2006 Oct; 13(7):375-80. PubMed ID: 17036091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
    Liu HJ; Krymskaya VP; Henske EP
    Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2.
    Maruyama H; Ohbayashi C; Hino O; Tsutsumi M; Konishi Y
    Pathol Int; 2001 Aug; 51(8):585-94. PubMed ID: 11564212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphangioleiomyomatosis and tuberous sclerosis.
    Hancock E; Tomkins S; Sampson J; Osborne J
    Respir Med; 2002 Jan; 96(1):7-13. PubMed ID: 11863212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary lymphangioleiomyomatosis in tuberous sclerosis. A case report.
    De Rosa N
    Pathologica; 2009 Oct; 101(5):186-9. PubMed ID: 20218060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphangioleiomyomatosis.
    Xu KF; Xu W; Liu S; Yu J; Tian X; Yang Y; Wang ST; Zhang W; Feng R; Zhang T
    Semin Respir Crit Care Med; 2020 Apr; 41(2):256-268. PubMed ID: 32279296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphangioleiomyomatosis and tuberous sclerosis complex.
    Chorianopoulos D; Stratakos G
    Lung; 2008; 186(4):197-207. PubMed ID: 18408969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).
    Urban T; Lazor R; Lacronique J; Murris M; Labrune S; Valeyre D; Cordier JF
    Medicine (Baltimore); 1999 Sep; 78(5):321-37. PubMed ID: 10499073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.